Novartis' Afinito Significantly Improves Progression-Free Survival In Advanced Nonfunctional GI and Lung NET

By: via Benzinga
Novartis (NYSE: NVS) announced Saturday, results of a Phase III pivotal study showing Afinitor® (everolimus) tablets reduced the risk of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.